

Serial No. 09/210,952

March 21, 2003

Page 2

Please amend claim 20 as shown on the following pages.

Marked-up sheets of the claim amendments are attached to this Amendment. Inserted material is underlined and deleted material is enclosed within brackets.

C

Serial No. 09/21(,952

March 21, 2003

Page 3

## Clean Copy of Amended Claim 20

1 20 (Twice amended). A substantially pure conopeptide selected from the group consisting of:

- (a) PnVIIA: Asp-Cys-Thr-Ser-Xaa<sub>1</sub>-Phe-Gly-Arg-Cys-Thr-Val-Asn-Ser-Xaa<sub>2</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Xaa<sub>2</sub>-Leu-Tyr-Ala-Phe-Xaa<sub>3</sub>-Ser (SEQ ID NO:6) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus has a free carboxyl group;
- (b) Tx6.4: Xaa<sub>1</sub>-Leu-Xaa<sub>2</sub>-Cys-Ser-Val-Xaa<sub>1</sub>-Phe-Ser-His-Cys-Thr-Lys-Asp-Ser-Xaa<sub>2</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Thr-Leu-Met-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Asp-Xaa<sub>1</sub> (SEQ ID NO:7) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus has a free carboxyl group;
- (c) Tx6.9: Xaa<sub>1</sub>-Xaa<sub>1</sub>-Arg-Xaa<sub>1</sub>-Gly-Gly-Cys-Met-Ala-Xaa<sub>1</sub>-Phe-Gly-Leu-Cys-Ser-Arg-Asp-Ser-Xaa<sub>2</sub>-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Val-Thr-Arg-Cys-Xaa<sub>2</sub>-Leu-Met-Xaa<sub>3</sub>-Phe-Xaa<sub>3</sub>-Xaa<sub>3</sub>-Asp-Xaa<sub>1</sub> (SEQ ID NO:8) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus has a free carboxyl group;
- (d) Tx6.6: Asp-Xaa<sub>1</sub>-Xaa<sub>1</sub>-Asp-Asp-Gly-Cys-Ser-Val-Xaa<sub>1</sub>-Gly-Xaa<sub>3</sub>-Cys-Thr-Val-Asn-Ala-Xaa<sub>2</sub>-Cys-Cys-Ser-Gly-Asp-Cys-His-Xaa<sub>2</sub>-Thr-Cys-Ile-Phe-Gly-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Val (SEQ ID NO:10) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus has a free carboxyl group;
- (e) Tx6.5: Gly-Met-Xaa<sub>1</sub>-Gly-Xaa<sub>2</sub>-Cys-Lys-Asp-Gly-Leu-Thr-Thr-Cys-Leu-Ala-Xaa<sub>3</sub>-Ser-Xaa<sub>2</sub>-Cys-Cys-Ser-Xaa<sub>2</sub>-Asp-Cys-Xaa<sub>2</sub>-Gly-Ser-Cys-Thr-Met-Xaa<sub>1</sub> (SEQ ID NO:11) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus has a free carboxyl group;
- (f) Gm6.7: Xaa<sub>2</sub>-Cys-Arg-Ala-Xaa<sub>1</sub>-Tyr-Ala-Xaa<sub>3</sub>-Cys-Ser-Xaa<sub>3</sub>-Gly-Ala-Gln-Cys-Cys-Ser-Leu-Leu-Met-Cys-Ser-Lys-Ala-Thr-Ser-Arg-Cys-Ile-Leu-Ala-Leu (SEQ ID NO:12) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus has a free carboxyl group;
- (g) Mr6.1: Asn-Gly-Gln-Cys-Xaa<sub>2</sub>-Asp-Val-Xaa<sub>1</sub>-Met-Xaa<sub>3</sub>-Cys-Thr-Ser-Asn-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Cys-Cys-Ser-Leu-Asp-Cys-Xaa<sub>2</sub>-Met-Tyr-Cys-Thr-Gln-Ile (SEQ ID

Serial No. 09/210,952

March 21, 2003

Page 4

NO:13) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu, Xaa<sub>3</sub> is Hyp and the C-terminus is amidated;

(g)

(h) Mr6.2:

Cys-Gly-Gly-Xaa<sub>1</sub>-Ser-Thr-Tyr-Cys-Xaa<sub>2</sub>-Val-Asp-Xaa<sub>2</sub>-Xaa<sub>2</sub>-Cys-Cys-Ser-Xaa<sub>2</sub>-Ser-Cys-Val-Arg-Ser-Tyr-Cys-Thr-Leu-Phe (SEQ ID NO:14) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu and the C-terminus is amidated; and

(h)

(i) Mr6.3:

Asn-Gly-Gly-Cys-Lys-Ala-Thr-Xaa<sub>1</sub>-Met-Ser-Cys-Ser-Ser-Gly-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Cys-Cys-Ser-Met-Ser-Cys-Asp-Met-Try-Cys (SEQ ID NO:15) wherein Xaa<sub>1</sub> is Trp, Xaa<sub>2</sub> is  $\gamma$ -Glu and the C-terminus is amidated.

C,  
CONT